Oxbridge BioMedTech business Sense Biodetection has raised $50 million in a Series B round led by Koch Disruptive Technologies – a subsidiary of £115 billion turnover US giant Koch, Inc., Inc, based in Wichita, Kansas.
The Series B also included participation from Sense’s existing investors Cambridge Innovation Capital, Earlybird Health, Cambridge entrepreneur Jonathan Milner and Mercia Asset Management.
The cash will advance commercialisation of the company’s Veros™ COVID-19 product and continue development of a portfolio of instrument-free, rapid molecular tests that enable improved access, outcomes, and value through patient-focused decentralised healthcare.
Sense Biodetection has operations in Cambridge and Oxford UK and Boston in the US. The Veros™ platform introduces novel and proprietary rapid molecular amplification technology to detect a variety of deadly and costly diseases.
